BioCentury | Nov 14, 2020
Product Development

ASH 2020 snapshot: efficacy data in hot emerging areas

...for AK117.Arch Oncology Inc., ImmuneOncia Therapeutics Inc., Invenra Inc. and Kahr Medical Ltd....
BioCentury | Nov 11, 2020
Deals

Previewing CD47 efficacy data at SITC & ASH: Data Byte

...for AK117.Arch Oncology Inc., ImmuneOncia Therapeutics Inc., Invenra Inc. and Kahr Medical Ltd....
BioCentury | Oct 17, 2020
Management Tracks

Merck KGaA’s Rossetti retires; plus moves at J&J, Innovent, eFFECTOR, Nautilus, Epirium and more

...and pathology at Duke University School of Medicine, its new president beginning Oct. 25.Cancer immunotherapy company Kahr Medical Ltd....
...Inc. Nautilus Biotechnology Inc. Medeor Therapeutics Inc. BeyondSpring Inc. MaxCyte Inc. Kedrion S.p.A. Jacobio Pharmaceutical Group Co. Ltd. eFFECTOR Therapeutics Inc. Epirium Bio Inc. Kahr Medical Ltd....
BioCentury | Mar 4, 2020
Finance

March 3 Quick Takes: Megarounds for Akouos, Element; plus venture rounds by Kahr, Primmune, Lipidio and Scipio and more

...in viral diagnostics, therapeutics and vaccine R&D. Israeli oncology play Kahr closes $18M round Jerusalem-based Kahr Medical Ltd....
...CD172a; SHPS-1) - Signal regulatory protein α Paul Bonanos, Associate Editor, and Hongjiang Li, Staff Writer Akouos Inc. CICC Kahr Medical Ltd. Primmune...
BioCentury | Dec 21, 2015
Financial News

Kahr Medical completes venture financing

...million Investors: Korea Investment Partners; Mirae Asset Venture Investment; DSC Investment; Flerie Invest AB Note: Kahr Medical...
BioCentury | Jan 20, 2014
Finance

Genzyme Ventures reboot

...new investments: $2 million in an April 2011 venture round in cancer and autoimmune company KAHR Medical Ltd....
BioCentury | Jun 27, 2011
Company News

KAHR, Recipharm deal

...negotiation to KAHR-102 after selecting the compound under a 2011 deal (see BioCentury, April 25). KAHR Medical Ltd....
BioCentury | Apr 25, 2011
Financial News

KAHR completes venture financing

KAHR Medical Ltd. , Jerusalem, Israel Business: Autoimmune Date completed: 4/14/11 Type: Venture financing Raised: $3 million Investors: sanofi-aventis Group ; Hadasit Bio-Holdings Note: Hadasit Bio-Holdings also converted $2 million of convertible loans. WIR Staff autoimmune...
BioCentury | Apr 25, 2011
Company News

KAHR, sanofi-aventis deal

...in KAHR and has committed to invest up to $1 million in a second close. KAHR Medical Ltd....
Items per page:
1 - 9 of 9
BioCentury | Nov 14, 2020
Product Development

ASH 2020 snapshot: efficacy data in hot emerging areas

...for AK117.Arch Oncology Inc., ImmuneOncia Therapeutics Inc., Invenra Inc. and Kahr Medical Ltd....
BioCentury | Nov 11, 2020
Deals

Previewing CD47 efficacy data at SITC & ASH: Data Byte

...for AK117.Arch Oncology Inc., ImmuneOncia Therapeutics Inc., Invenra Inc. and Kahr Medical Ltd....
BioCentury | Oct 17, 2020
Management Tracks

Merck KGaA’s Rossetti retires; plus moves at J&J, Innovent, eFFECTOR, Nautilus, Epirium and more

...and pathology at Duke University School of Medicine, its new president beginning Oct. 25.Cancer immunotherapy company Kahr Medical Ltd....
...Inc. Nautilus Biotechnology Inc. Medeor Therapeutics Inc. BeyondSpring Inc. MaxCyte Inc. Kedrion S.p.A. Jacobio Pharmaceutical Group Co. Ltd. eFFECTOR Therapeutics Inc. Epirium Bio Inc. Kahr Medical Ltd....
BioCentury | Mar 4, 2020
Finance

March 3 Quick Takes: Megarounds for Akouos, Element; plus venture rounds by Kahr, Primmune, Lipidio and Scipio and more

...in viral diagnostics, therapeutics and vaccine R&D. Israeli oncology play Kahr closes $18M round Jerusalem-based Kahr Medical Ltd....
...CD172a; SHPS-1) - Signal regulatory protein α Paul Bonanos, Associate Editor, and Hongjiang Li, Staff Writer Akouos Inc. CICC Kahr Medical Ltd. Primmune...
BioCentury | Dec 21, 2015
Financial News

Kahr Medical completes venture financing

...million Investors: Korea Investment Partners; Mirae Asset Venture Investment; DSC Investment; Flerie Invest AB Note: Kahr Medical...
BioCentury | Jan 20, 2014
Finance

Genzyme Ventures reboot

...new investments: $2 million in an April 2011 venture round in cancer and autoimmune company KAHR Medical Ltd....
BioCentury | Jun 27, 2011
Company News

KAHR, Recipharm deal

...negotiation to KAHR-102 after selecting the compound under a 2011 deal (see BioCentury, April 25). KAHR Medical Ltd....
BioCentury | Apr 25, 2011
Financial News

KAHR completes venture financing

KAHR Medical Ltd. , Jerusalem, Israel Business: Autoimmune Date completed: 4/14/11 Type: Venture financing Raised: $3 million Investors: sanofi-aventis Group ; Hadasit Bio-Holdings Note: Hadasit Bio-Holdings also converted $2 million of convertible loans. WIR Staff autoimmune...
BioCentury | Apr 25, 2011
Company News

KAHR, sanofi-aventis deal

...in KAHR and has committed to invest up to $1 million in a second close. KAHR Medical Ltd....
Items per page:
1 - 9 of 9